Wednesday, December 01, 2021 11:28:39 AM
Is it possible to write this statement with a straight face? Perhaps you are referring to the "facts, not speculation" contained in their August 21, 2020 press release:
"The Company currently continues to anticipate reporting topline trial data in September [2020], and anticipates providing further updates as the process progresses."
Here's the link
Is that what you meant? How about:
- The many other lies and misleading statements they've made over the years about the conclusion of the trial being imminent (literally dozens of examples)?
- Or how they just can't seem to be able to release results from a trial they locked data on 14 months ago because of COVID-related delays (total bs)?
- Or how they are prepping an article for publication (that was 14 months ago - where is it?)?
- Or how DCVax-L was approved for treatment in Switzerland (total lie)?
- Or how they used a press release to announce the hiring of Kevin Duffy with great fanfare about the all-important role he would play, but when he ditched the company seven months later they never said a word (no press release)?
- Or how they conducted an interim efficacy assessment in 2015, as they had said previously in a press release that they would, but never disclosed to shareholders that they had conducted the IA, never disclosed the results of the IA to shareholders, but saw trial enrollment halted by the FDA and then suddenly changed the whole focus of the trial away from the primary endpoint of PFS and toward the secondary endpoint of OS?
- Or how they allegedly officially changed the endpoints of the trial in 2020, at least for the European regulators (as discovered by someone who posts on iHub) but never disclosed it to shareholders, and still to this day have provided no explanation about what the actual endpoints are and why the endpoints remain unchanged in the USA under the FDA trial description?
- Or how they released an interim data report in 2018 that totally avoided any analysis of the trial's (then) primary endpoint?
- Or how they are right now, at this very moment, withholding material information from shareholders based on what they wrote in the very same press release cited above:
"As previously reported, the statisticians’ work is estimated to take a couple of weeks."
"When their computations are completed, the Company will receive the results of those computations and thereby become unblinded."
If the company is unblinded, as they say they are in the August 2020 press release, then where is the data? They said they locked the data in early October 2020, so according to their own words, they became unblinded "a couple of weeks" later. Right? It is now December 1, 2021. They have not released the data and we have not been given any updates - also as promised in the same press release. Are these the facts you are talking about?
Look, I could go on and on and on. There is so much more, and that doesn't even begin to touch on the fact that the company has had its hand slapped by the SEC more than once for inadequate reporting in its regulatory filings. Are these the facts you are talking about? Is this the evidence you are referring to in their PRs? Yeah, that's what I thought.
This company is a joke. It is run by liars, and they are running a scam. The financing deal they just completed with a usurious low-life scoundrel just bought them 8 more months with no TLD. That's what they did. They just raised enough money to pay of their previous debt obligation, and pay their $600,000 salaries, all while not releasing top line data!
How is it possible that after all the lies they've told, after all the misleading information they have put out, after all the false promises they have made and broken going back almost 20 years, that anyone could have the impression NWBO is "in the business of releasing facts, not speculation"? It's upside-down world. Astounding. It's just amazing.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM